期刊文献+

高效液相色谱法测定培美曲塞二钠原料药中有关物质

Determination of related substances in pemetrexed disodium by RP-HPLC
原文传递
导出
摘要 建立了高效液相色谱法测定培美曲塞二钠原料药有关物质的方法。采用Zorbax SB-C8(4.6 mm i.d.×150 mm,3.5μm)色谱柱,以0.025 mol/L乙酸钠溶液(用冰乙酸调p H至5.5)为流动相A,乙腈为流动相B,梯度洗脱,流速为1.0 m L/min;柱温35℃;检测波长250 nm;进样体积20μL。在该条件下主成分与有关物质的分离度良好,在测定的范围内具有良好的线性关系(相关系数r>0.999)、精密度和稳定性。方法能够对培美曲塞二钠原料药的主要杂质进行有效的分离和检测,可用于该产品的质量控制。 To establish a method for determination of the related substances of pemetrexed disodium. An HPLC gradient elution method and Zorbax SB-Cs (4.6 × 150 mm, 3.5 μm) column was used in this study. The mobile phase A was 0. 025 mol/L sodium acetate (adjusted to pH 5.5 with acetic acid) and mobile phase B was acetonitrile. The flow rate was set as 1.0 mL/min, the column temperature was 35 ℃ , the detection wavelength was 250 nm and the injection volume was 20 μL. High resolution was obtained between the peaks of main content and related species. This method also exhibited good linearity (correlation coefficients r 〉 0. 999) in the detection range, excellent precision and high stability. With the high specificity, sensitivity and repeatability, this method can be applied to the efficient separation and detection of the impurities in pemetrexed disodium, which is promising in the quality control of this medication.
出处 《分析试验室》 CAS CSCD 北大核心 2015年第9期1018-1021,共4页 Chinese Journal of Analysis Laboratory
基金 国家手性制药工程技术中心创新平台建设专项(2008ZHZX1A0902)资助
关键词 培美曲塞二钠 有关物质 高效液相色谱法 cPemetrexed disodium Related substances HPLC
  • 相关文献

参考文献6

二级参考文献43

  • 1李树婷,马飞,孙燕.抗肿瘤代谢新药——培美曲塞[J].癌症进展,2005,3(5):471-476. 被引量:73
  • 2李凤华,张克俊.紫外分光光度法测定1%盐酸丁卡因注射液的含量[J].安徽医药,2005,9(8):594-594. 被引量:1
  • 3[1]HANAUSKE AR,CHEN V,PAOLETTI P,et al.Pemetrexed disodium:a novel antifolate clinically active against multiple solid tumors [J].Oncologist,2001,6(4):363-373.
  • 4[2]ADJEI AA.Pemetrexed:a multitargeted antifolate agent with promising activity in solid tumors [J].Ann Oncol,2000,11(10):1335-1341.
  • 5[3]SCHULTZ RM,PATEL VF,WORZALLA JF,et al.Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate,LY231514 [J].Anticancer Res,1999,19(1A):437-443.
  • 6[4]TEICHER BA,CHEN V,SHIH C,et al.Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.[J].Clin Cancer Res,2000,6(3):1016-1023.
  • 7[5]FOSSELLA FV,GATZEMEIER U.Phase I trials of pemetrexed [J].Semin Oncol,2002,29(2 Suppl 5):8-16.
  • 8[6]RINALDI DA,KUHN JG,BURRIS HA,et al.A phase I evaluation of multitargeted antifolate (MTA,LY231514),administered every 21 days,utilizing the modified continual reassessment method for dose escalation [J].Cancer Chemother Pharmacol,1999,44(5):372-380.
  • 9[7]THODTMANN R,DEPENBROCK H,DUMEZ,et al.Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin [J].J Clin Oncol,1999,17(10):3009-3016.
  • 10[8]HUGHES A,CALVERT P,AZZABI A,et al.Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma [J].J Clin Oncol,2002,20(16):3533-3544.

共引文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部